Last reviewed · How we verify
NCT00179842
Immune Ablation and Stem Cell Support for Crohn's Disease
Phase 2 trial testing Stem Cell Transplant in Crohn Disease. Withdrawn.
19 December 2008
Quick facts
| Lead sponsor | Ann & Robert H Lurie Children's Hospital of Chicago |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 22 March 2007 |
| Primary completion | 19 December 2008 |
| Estimated completion | 19 December 2008 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Stem Cell Transplant — full drug profile →
Conditions studied
- Crohn Disease — all drugs for Crohn Disease →
Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Who can join
Eligibility, any sex, with Crohn Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators anticipate that this study will also form the basis to clarify further the role of the immune system in Crohn's disease.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Stem cells for luminal, fistulizing, and perianal inflammatory bowel disease: a comprehensive updated review of the literature.
Turse EP, Dailey FE, Naseer M, Partyka EK, et al · · 2018 · cited 10× · PMID 30568468 · DOI 10.2147/sccaa.s135414
Verify or expand the search:
- PubMed search for NCT00179842
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Stem Cell Transplant
Trials testing the same drug.
- NCT02512497 — Romidepsin Maintenance After Allogeneic Stem Cell Transplantation · Phase 1 · completed
- NCT02589145 — Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffus · Phase 1, PHASE2 · terminated
- NCT02162420 — Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia · NA · completed
- NCT02098109 — Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologou · Phase 2 · completed
- NCT00968760 — CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies · Phase 1 · completed
Other recruiting trials for Crohn Disease
Currently open trials in the same condition.
- NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
- NCT07310095 — A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) · Phase 4 · recruiting
- NCT07364734 — Epidemiological Characteristics and Efficacy Evaluation of Difficult-To-Treat Crohn's Disease · recruiting
- NCT07170462 — Cranberry and Gut Health in Crohn's Disease · EARLY_PHASE1 · recruiting
- NCT07196722 — A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease · Phase 2, PHASE3 · recruiting
Other Ann & Robert H Lurie Children's Hospital of Chicago trials
Trials by the same sponsor.
- NCT07411300 — Supporting Caregivers Following Mental Health Emergency Department Visits · NA · recruiting
- NCT06986148 — Comparing Antibiotic Treatment Strategies for Children With Pneumonia in Outpatient Settings: (STAMPP) · NA · recruiting
- NCT07372898 — Impact of Hospital to Home: Optimizing Preterm Infant Environment for Surgical Neonates and Their Parents (H-HOPE) · NA · recruiting
- NCT07216326 — Our Voices Matter: Intervention for Depression in Youth · NA · recruiting
- NCT06689943 — Pain After Strabismus Surgery · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00179842 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ann & Robert H Lurie Children's Hospital of Chicago
- Last refreshed: 10 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00179842.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing